BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of ...
Praxis Precision Medicines (NASDAQ:PRAX) announced Friday that the company will advance its Essential3 program for its lead asset ulixacaltamide against the neurological disorder essential tremor ...
Charles Schwab Investment Management Inc. boosted its position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Free Report) by 4.3% in the fourth quarter, Holdings Channel.com reports.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback